Coloplast A/S (OTCMKTS:CLPBY) Stock Rating Upgraded by Royal Bank of Canada

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by equities researchers at Royal Bank of Canada from a “hold” rating to a “moderate buy” rating in a report released on Monday,Zacks.com reports.

Several other analysts also recently issued reports on the company. Hsbc Global Res upgraded Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th. UBS Group raised shares of Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, Sanford C. Bernstein upgraded shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th.

Coloplast A/S Stock Performance

Shares of OTCMKTS:CLPBY opened at $11.10 on Monday. The stock has a fifty day moving average of $11.11 and a 200-day moving average of $12.26. Coloplast A/S has a one year low of $10.54 and a one year high of $14.34. The company has a current ratio of 1.02, a quick ratio of 0.66 and a debt-to-equity ratio of 0.92.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings data on Tuesday, February 4th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. Research analysts forecast that Coloplast A/S will post 0.31 EPS for the current year.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.